40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +1 617 455 4188

Accelerating mRNA Drug Substance Process Scale Up and Manufacturing

Built with biopharmaceutical industry insights, this in-person conference will bring together key opinion leaders to delve deep into the key remaining challenges associated with mRNA process scale up and manufacturing towards regulatory harmonization by optimizing in vitro transcription, purification and analytical validation mRNA drug substance.

With 200+ attendees from large pharma, innovative biotech and KOLs of academia who are ready to discuss how the future mRNA process development and manufacturing is shaping in accordance with regulatory expectations and emerging tools and technologies to support the development of scalable and commercially viable mRNA-based therapeutics and vaccines, join us in Boston to hear how they address the major challenges facing the industry.

URLs:
Tickets: https://go.evvnt.com/1170386-2?pid=1052
Brochure: https://go.evvnt.com/1170386-3?pid=1052

Prices:
Drug Developer - Conference + 2 Workshops: USD 4097.00,
Drug Developer - Conference + 1 Workshop: USD 3498.00,
Drug Developer - Conference Only: USD 2899.00,
Academic - Conference + 2 Workshops: USD 3497.00,
Academic - Conference + 1 Workshop: USD 2998.00,
Academic - Conference Only: USD 2499.00,
Service Provider - Conference + 2 Workshops: USD 4897.00,
Service Provider - Conference + 1 Workshop: USD 4198.00,
Service Provider - Conference Only: USD 3499.00

Ales Stancar, Managing Director, BIA Separations, Andreas Kuhn, SVP - RNA Biochemistry and Manufacturing, BioNTech SE, Camilla Foged, Professor - Vaccine Design and Delivery, University of Copenhagen, Christopher Kelly, Director - Regulatory Affairs CMC, Moderna, Craig Martin, Professor - Chemistry, University of Massachusetts Amherst, David Cirelli, Senior Director - Analytical Research and Development, Pfizer, Dushyant Varshney, CTO, Arcturus Therapeutics, Elaine Peters, Director - Cell and Gene Therapy Analytical Capabilities, Genentech, Elvan Cavac, Scientist II - mRNA Upstream Process Development, Tessera Therapeutics, Emily English, Senior Director - Quality, Cartesian Therapeutics, Gautam Sanyal, Principal Consultant, Vaccine Analytics LLC, Harris Makatsoris, Professor - Sustainable Manufacturing Systems, King's College London, Hiroshi Abe, Professor, Nagoya University, Hirra Hussain, Senior Scientist, CPI, Hunter Stitik, Director - Enterprise Science and Innovation, ThermoFisher Scientific, Jin Zhou, Executive Director - Process Development; mRNA and Protein Biologics, Ultragenyx Pharmaceutical, Khaled Yamout, Senior Director, Manufacturing and Quality Control, TriLink BioTechnologies, Kristie Bloom, Researcher, University of the Witwatersrand, Madelyn Johnstone- Robertson, BioProcess Engineer, Afrigen Biologics, Mark McElligott, Owner/Principal Engineer, BioX, Martin Carvalho, Head - Quality, mRNA Centre of Excellence, Sanofi, Petro Terblanche, Managing Director, Afrigen Biologics, Philippe Alexandre Gilbert, Senior Program Officer - CMC, Bill and Melinda Gates Foundation, Rachit Jain, Director - Process Development, Tessera Therapeutics, Scott Alderucci, Director - Process Development, Curia, Serena Smith, Director - Strategy and Market Intelligence, Thermo Fisher Scientific, Shefal Parikh, Director - mRNA Process Development, Beam Therapeutics, So-ching, Brazer Senior Director - Global Regulatory Affairs CMC, Ultragenyx Pharmaceutical, Srinivasulu Bandi, Director - BioProcess Development, Senda Biosciences, Steve Pascolo, Professor, University Hospital of Zürich, Thomas Aune, Professor, Vanderbilt University Medical Center, Thomas Nsenda, Director Business Development EMEA, Pfanstiehl, Vijay Dhawan, Head - Analytical Development/QC, Genomic Medicine, Sanofi, Xinyue Zhang, Investigator - mRNA Process and Analytical Development, GeneLeap Biotech, Zheng Meng, Senior Director - Analytical Development, Ultragenyx Pharmaceutical